<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Boehringer Ingelheim Corporation
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        72701865
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       138739
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   As the US headquarters of German drug maker
   <company id="91087">
    Boehringer Ingelheim
   </company>
   , Boehringer Ingelheim Corporation oversees about half a dozen stateside subsidiaries that produce and sell drugs (both prescription and over-the-counter), animal health products, and chemicals for the US market. It sells its prescription and OTC products through its largest unit
   <company id="138554">
    Boehringer Ingelheim Pharmaceuticals
   </company>
   . Additionally, the firm's
   <company id="100385">
    Roxane Laboratories
   </company>
   (which the company is selling) makes generic drugs, and its
   <company id="108892">
    Ben Venue Laboratories
   </company>
   is a contract pharmaceutical manufacturer and provides drug development services to other pharmaceutical companies.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Operations.flsnp" />
  <p>
   The company's Boehringer Ingelheim Vetmedica unit is a leading US maker of health products for farm animals and pets, while Boehringer Ingelheim Chemicals produces active pharmaceutical ingredients used in drugmaking.
  </p>
  <p>
   Through its Pharmaceuticals subsidiary, Boehringer Ingelheim Corporation serves as one of its parent company's major research centers, with particular focus on cardiovascular disease, immunology, and inflammatory conditions.
  </p>
  <p>
   Boehringer Ingelheim has a collaboration agreement with Evotec OAI and Evotec Neurosciences to jointly identify and develop small molecule therapies acting on selected G-Protein Coupled Receptors. Additionally, the company has a collaboration and license agreement with AbGenomics that gives Boehringer Ingelheim the global exclusive rights to develop, manufacture, and commercialize an AbGenomics therapeutic monoclonal antibody.
  </p>
  <p>
   Geographic ReachThe company has operations in Ridgefield, Connecticut; Cleveland and Columbus, Ohio; St. Joseph, Missouri; and Fremont, California.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   In 2014 Boehringer Ingelheim Pharmaceuticals and
   <company id="10509">
    Eli Lilly
   </company>
   received
   <company id="144161">
    FDA
   </company>
   approval for their Jardiance tablets to improve blood glucose levels in adults with type 2 diabetes. The FDA also approved Striverdi Respimat Inhalation Spray Î¼g as a maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. Other FDA-approved treatments include Pradaxa for the treatment of deep venous thrombosis and pulmonary embolism (2014) and Glyxambi tablets for the treatment of type 2 diabetes.
  </p>
  <p>
   The company announced plans to lay off 724 employees across the US in 2016. The announcement comes amid a number of corporate restructurings such as the group's withdrawal from generics operations and an increased focus on animal health.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
